within Pharmacolibrary.Drugs.ATC.L;

model L01XF03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.2,
    Cl             = 0.03383333333333333,
    adminDuration  = 600,
    adminMass      = 0.3,
    adminCount     = 1,
    Vd             = 0.011,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0025,
    Tlag           = 12.0
  );

  annotation(Documentation(
    info ="<html><body><p>Bexarotene is a synthetic retinoid, selective agonist of retinoid X receptors (RXRs), used primarily for the treatment of cutaneous T-cell lymphoma (CTCL). It is an FDA-approved therapy for patients with refractory or persistent CTCL.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients with advanced malignancies and CTCL, both sexes, typical age range 40-75 years.</p><h4>References</h4><ol><li><p>Chen, L, et al., &amp; Zhang, D (2014). Bexarotene nanocrystal-Oral and parenteral formulation development, characterization and pharmacokinetic evaluation. <i>European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V</i> 87(1) 160–169. DOI:<a href=&quot;https://doi.org/10.1016/j.ejpb.2013.12.005&quot;>10.1016/j.ejpb.2013.12.005</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24333772/&quot;>https://pubmed.ncbi.nlm.nih.gov/24333772</a></p></li><li><p>Ren, S, et al., &amp; Du, G (2020). A Novel Co-Crystal of Bexarotene and Ligustrazine Improves Pharmacokinetics and Tissue Distribution of Bexarotene in SD Rats. <i>Pharmaceutics</i> 12(10) –. DOI:<a href=&quot;https://doi.org/10.3390/pharmaceutics12100906&quot;>10.3390/pharmaceutics12100906</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32977470/&quot;>https://pubmed.ncbi.nlm.nih.gov/32977470</a></p></li><li><p>Lee, JB, et al., &amp; Shin, BS (2019). Quantitative Prediction of Oral Bioavailability of a Lipophilic Antineoplastic Drug Bexarotene Administered in Lipidic Formulation Using a Combined In Vitro Lipolysis/Microsomal Metabolism Approach. <i>Journal of pharmaceutical sciences</i> 108(2) 1047–1052. DOI:<a href=&quot;https://doi.org/10.1016/j.xphs.2018.09.025&quot;>10.1016/j.xphs.2018.09.025</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30268807/&quot;>https://pubmed.ncbi.nlm.nih.gov/30268807</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01XF03;
